Artificial intelligence is transforming pharmaceutical R&D. At Novaawell, our computational chemistry team uses deep learning models to screen millions of molecular compounds in days rather than years. Our AI pipeline has identified three promising drug candidates currently in Phase II trials. By combining generative chemistry with predictive toxicology models, we’ve reduced early-stage failure rates by 45%, accelerating the path from lab bench to patient bedside.
innovation